Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
NCT ID: NCT05874310
Last Updated: 2023-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
18 participants
INTERVENTIONAL
2023-02-01
2027-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
NCT06492850
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
NCT04671433
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
NCT06646289
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
NCT04794101
Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
NCT03252847
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose FT-002
Intraocular injection of a single low dose of FT-002
FT-002
Comparison of different dosages of FT-002
Intermediate dose FT-002
Intraocular injection of a single Intermediate dose of FT-002
FT-002
Comparison of different dosages of FT-002
High dose FT-002
Intraocular injection of a single High dose of FT-002
FT-002
Comparison of different dosages of FT-002
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FT-002
Comparison of different dosages of FT-002
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
8 Years
45 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eye & ENT Hospital of Fudan University
OTHER
Peking Union Medical College Hospital
OTHER
Henan Provincial People's Hospital
OTHER
Frontera Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gezhi Xu
Role: PRINCIPAL_INVESTIGATOR
Eye & ENT Hospital of Fudan University
Ruifang Sui
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Eye & ENT hospital of Fudan university
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ruifang Sui, Professor
Role: primary
Gezhi Xu, Professor
Role: primary
Jihong Wu, Professor
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FT002RP-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.